Relay Therapeutics, Inc. Common Stock

Day range

$17.94 – $18.66

Open

$18.33

Prev close

$18.18

Volume

1.59M

Market cap

$3.98B

Shares out

219.14M

P/E

—

P/S

384.93

P/B

4.48

P/FCF

—

ROE

-32.2%

ROA

-29.6%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Public offeringAug 6, 2026

  On August 6, 2026, the Company entered into an amendment to the Original Sales Agreement (the "Sales Agreement Amendment," and collectively with the Original Sales Agreement, the "Sales Agreement") to increase the size of the at-the-market offering program from $250,000,000 to $462,978,049... The New Prospectus Supplement covers the offer and sale of up to $212,978,049 of shares of Common Stock (the "Additional Shares") from time to time through TD Cowen, acting as the Company's sales agent.

• Annual meeting resultsJun 9, 2026

  On June 9, 2026, the Company held its Annual Meeting to consider and vote on the four proposals set forth below... The final voting results are set forth below. Proposal 1. Election of directors... Proposal 2. Non-binding advisory vote on executive compensation... Proposal 3. Ratification of appointment of independent registered public accounting firm... Proposal 4. Approval of amendment to the Company's Fourth Amended and Restated Certificate of Incorporation, as amended.

• Underwriting agreementMay 21, 2026

  On May 20, 2026, Relay Therapeutics, Inc. (the "Company") entered into an Underwriting Agreement (the "Underwriting Agreement") with Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters listed on Schedule 1 thereto (collectively, the "Underwriters"), relating to an underwritten public offering (the "Offering") of 22,916,667 shares of the Company's common stock, $0.001 par value per share (the "Common Stock"), at a price to the public of $12.00 per share. The Company granted the Underwriters a 30-day option to purchase, at the public offering price less underwriting discounts and commissions, up to an additional 3,437,500 shares of Common Stock which the Underwriters exercised in full on May 21, 2026. The Company estimates net proceeds from the Offering, after deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company, will be approximately $296.8 million.

• Clinical trial resultsMay 19, 2026

  On May 19, 2026, the Company announced initial clinical data from the Phase 2 ReInspire trial of zovegalisib in vascular anomalies. The data reported today are from Part 1 of the study in the adults and adolescents cohort (patients 12 years or older), which featured randomized dose selection across three doses. As of the April 15, 2026 data cut-off date, 32 total patients were enrolled and randomized to the following dose cohorts: N=11 at 100mg twice daily, N=11 at 300mg BID, and N=10 at 400mg BID.

• Partnership or collaborationApr 27, 2026

  Pursuant to the terms of a clinical trial supply agreement, Pfizer, Inc. ('Pfizer') has agreed to supply atirmociclib for the experimental arm in combination with zovegalisib and the palbociclib portion of the control arm for use in the planned study. The Company will sponsor, fully operationalize and fund the planned Phase 3 trial.

Days to cover

12.6

Short interest

46.75M

Avg volume

3.71M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Elevar Therapeutics Announces FDA Approval of Lyrfigtu (Lirafugratinib) as Second-line Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement Treatment Option
  positiveGlobeNewswire Inc.· Sep 23, 2026
• Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
  neutralGlobeNewswire Inc.· Sep 1, 2026
• Is Relay Therapeutics a Buy After Promising Trial Results?
  positiveThe Motley Fool· May 22, 2026
• Relay Therapeutics Announces Pricing of Public Offering of Common Stock
  positiveGlobeNewswire Inc.· May 20, 2026
• Why Relay Therapeutics Stock Popped on Wednesday
  positiveThe Motley Fool· May 20, 2026